SCNI

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is a development-stage biopharmaceutical company founded in 2003 and headquartered in Jerusalem, Israel. Originally incorporated as BiondVax Pharmaceuticals Ltd., the company rebranded to its current name in September 2023. Scinai went public in 2015 and focuses on developing innovative therapeutic solutions for infectious diseases, autoimmune conditions, and other medical conditions. The company operates through two primary business segments: research and development of proprietary nanobody therapeutics, and contract development and manufacturing organization (CDMO) services for other biotechnology companies.